A One Health approach to antimicrobial resistance surveillance: is there a business case for it?
Highlights • Antimicrobial resistance surveillance requires an integrated One Health approach. • A conceptual framework for a One Health approach to surveillance is presented. • Current surveillance systems (from local to global) fall short of this framework. • Policy decisions favour economic evide...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2016-10, Vol.48 (4), p.422-427 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 427 |
|---|---|
| container_issue | 4 |
| container_start_page | 422 |
| container_title | International journal of antimicrobial agents |
| container_volume | 48 |
| creator | Queenan, Kevin Häsler, Barbara Rushton, Jonathan |
| description | Highlights • Antimicrobial resistance surveillance requires an integrated One Health approach. • A conceptual framework for a One Health approach to surveillance is presented. • Current surveillance systems (from local to global) fall short of this framework. • Policy decisions favour economic evidence, so a business case is proposed. • Broad benefits to society, animal welfare, ecosystem health and more are included. |
| doi_str_mv | 10.1016/j.ijantimicag.2016.06.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1824225998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857916301832</els_id><sourcerecordid>1824225998</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-f6cede4fde0c74d5efc3bd86affa95cfab6de35a452a1552ca275e4d447d69603</originalsourceid><addsrcrecordid>eNqNkU-LFDEQxYMo7rj6FSTevPSYv90dD8oyrK6wsAf1HNNJtZO2p3tMpRf225tmRhFPQkFIeFUv71eEvOJsyxmv3wzbOLgpx0P07vtWlKctK8XVI7LhbSOqxnD5mGyYEapqdWMuyDPEgTGupdJPyYVolKm1lBvy7YreTUBvwI15T93xmGbn9zTP9GyQ5i66kSbAiNlNHigu6R7iOK6XtzQizXtIQB3tFowTIFLvEGg_Jxrz--fkSe9GhBfn85J8_XD9ZXdT3d59_LS7uq28amWu-tpDANUHYL5RQUPvZRfa2vW9M9r3rqsDSO2UFo5rLbwTjQYVlGpCbWomL8nr09yS4OcCmO0hoof1mzAvaHkrlBDamLZIzUlawiEm6O0xxYNLD5YzuwK2g_0LsF0BW1aKq9L78myzdAcIfzp_Ey2C3UkAJex9hGTRRyioQkzgsw1z_C-bd_9M8WOcimz8AQ-Aw7ykqdC03KKwzH5eN70umteS8VYK-QtXIqkC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1824225998</pqid></control><display><type>article</type><title>A One Health approach to antimicrobial resistance surveillance: is there a business case for it?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Queenan, Kevin ; Häsler, Barbara ; Rushton, Jonathan</creator><creatorcontrib>Queenan, Kevin ; Häsler, Barbara ; Rushton, Jonathan</creatorcontrib><description>Highlights • Antimicrobial resistance surveillance requires an integrated One Health approach. • A conceptual framework for a One Health approach to surveillance is presented. • Current surveillance systems (from local to global) fall short of this framework. • Policy decisions favour economic evidence, so a business case is proposed. • Broad benefits to society, animal welfare, ecosystem health and more are included.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2016.06.014</identifier><identifier>PMID: 27496533</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>AMR ; Animals ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antimicrobial resistance ; Business case ; Cost-Benefit Analysis ; Drug Resistance, Bacterial ; Drug Utilization ; Economics ; Epidemiological Monitoring ; Global Health ; Humans ; Infectious Disease ; One Health ; Surveillance</subject><ispartof>International journal of antimicrobial agents, 2016-10, Vol.48 (4), p.422-427</ispartof><rights>Elsevier B.V. and International Society of Chemotherapy</rights><rights>2016 Elsevier B.V. and International Society of Chemotherapy</rights><rights>Copyright © 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-f6cede4fde0c74d5efc3bd86affa95cfab6de35a452a1552ca275e4d447d69603</citedby><cites>FETCH-LOGICAL-c483t-f6cede4fde0c74d5efc3bd86affa95cfab6de35a452a1552ca275e4d447d69603</cites><orcidid>0000-0001-7066-6877</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0924857916301832$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27496533$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Queenan, Kevin</creatorcontrib><creatorcontrib>Häsler, Barbara</creatorcontrib><creatorcontrib>Rushton, Jonathan</creatorcontrib><title>A One Health approach to antimicrobial resistance surveillance: is there a business case for it?</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Highlights • Antimicrobial resistance surveillance requires an integrated One Health approach. • A conceptual framework for a One Health approach to surveillance is presented. • Current surveillance systems (from local to global) fall short of this framework. • Policy decisions favour economic evidence, so a business case is proposed. • Broad benefits to society, animal welfare, ecosystem health and more are included.</description><subject>AMR</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antimicrobial resistance</subject><subject>Business case</subject><subject>Cost-Benefit Analysis</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug Utilization</subject><subject>Economics</subject><subject>Epidemiological Monitoring</subject><subject>Global Health</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>One Health</subject><subject>Surveillance</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU-LFDEQxYMo7rj6FSTevPSYv90dD8oyrK6wsAf1HNNJtZO2p3tMpRf225tmRhFPQkFIeFUv71eEvOJsyxmv3wzbOLgpx0P07vtWlKctK8XVI7LhbSOqxnD5mGyYEapqdWMuyDPEgTGupdJPyYVolKm1lBvy7YreTUBvwI15T93xmGbn9zTP9GyQ5i66kSbAiNlNHigu6R7iOK6XtzQizXtIQB3tFowTIFLvEGg_Jxrz--fkSe9GhBfn85J8_XD9ZXdT3d59_LS7uq28amWu-tpDANUHYL5RQUPvZRfa2vW9M9r3rqsDSO2UFo5rLbwTjQYVlGpCbWomL8nr09yS4OcCmO0hoof1mzAvaHkrlBDamLZIzUlawiEm6O0xxYNLD5YzuwK2g_0LsF0BW1aKq9L78myzdAcIfzp_Ey2C3UkAJex9hGTRRyioQkzgsw1z_C-bd_9M8WOcimz8AQ-Aw7ykqdC03KKwzH5eN70umteS8VYK-QtXIqkC</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Queenan, Kevin</creator><creator>Häsler, Barbara</creator><creator>Rushton, Jonathan</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7066-6877</orcidid></search><sort><creationdate>20161001</creationdate><title>A One Health approach to antimicrobial resistance surveillance: is there a business case for it?</title><author>Queenan, Kevin ; Häsler, Barbara ; Rushton, Jonathan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-f6cede4fde0c74d5efc3bd86affa95cfab6de35a452a1552ca275e4d447d69603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>AMR</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antimicrobial resistance</topic><topic>Business case</topic><topic>Cost-Benefit Analysis</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug Utilization</topic><topic>Economics</topic><topic>Epidemiological Monitoring</topic><topic>Global Health</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>One Health</topic><topic>Surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Queenan, Kevin</creatorcontrib><creatorcontrib>Häsler, Barbara</creatorcontrib><creatorcontrib>Rushton, Jonathan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Queenan, Kevin</au><au>Häsler, Barbara</au><au>Rushton, Jonathan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A One Health approach to antimicrobial resistance surveillance: is there a business case for it?</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>48</volume><issue>4</issue><spage>422</spage><epage>427</epage><pages>422-427</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Highlights • Antimicrobial resistance surveillance requires an integrated One Health approach. • A conceptual framework for a One Health approach to surveillance is presented. • Current surveillance systems (from local to global) fall short of this framework. • Policy decisions favour economic evidence, so a business case is proposed. • Broad benefits to society, animal welfare, ecosystem health and more are included.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27496533</pmid><doi>10.1016/j.ijantimicag.2016.06.014</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-7066-6877</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2016-10, Vol.48 (4), p.422-427 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1824225998 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | AMR Animals Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antimicrobial resistance Business case Cost-Benefit Analysis Drug Resistance, Bacterial Drug Utilization Economics Epidemiological Monitoring Global Health Humans Infectious Disease One Health Surveillance |
| title | A One Health approach to antimicrobial resistance surveillance: is there a business case for it? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T13%3A47%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20One%20Health%20approach%20to%20antimicrobial%20resistance%20surveillance:%20is%20there%20a%20business%20case%20for%20it?&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Queenan,%20Kevin&rft.date=2016-10-01&rft.volume=48&rft.issue=4&rft.spage=422&rft.epage=427&rft.pages=422-427&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2016.06.014&rft_dat=%3Cproquest_cross%3E1824225998%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1824225998&rft_id=info:pmid/27496533&rft_els_id=S0924857916301832&rfr_iscdi=true |